MedDataX Logo

Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm

NCT ID: NCT02814201

Last Updated: 2016-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the clinical expression of these two diseases is characterized by a combination of motor and cognitive disorders, but with two opposing patterns of dysfunction. Action slowing has been demonstrated in both of these diseases and has been extensively studied in Parkinson's disease, suggesting a perceptive-cognitive origin. Far fewer studies have been conducted in Huntington's disease. However, all of these studies were performed with different methodologies in small cohorts and the value of the proposed study is to use a validated and standardized computerized mental chronometry paradigm, providing a better understanding of the mechanisms of action slowing in these two diseases and to more clearly define a disease-specific profile.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Huntington Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Motor slowing Computerized mental chronometry paradigm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson best-On

two hours after taking two tablets of 125 mg dispersible Modopar®

SRT

Intervention Type BEHAVIORAL

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Parkinson worst-off

after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)

SRT

Intervention Type BEHAVIORAL

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Huntington

SRT

Intervention Type BEHAVIORAL

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Control

Data collected from the existing database

SRT

Intervention Type BEHAVIORAL

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SRT

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Agreeing to participate in the study
* French mother tongue
* MMSE \> 20/30
* Specific to the MP and MH:

* Parkinson's disease:

* defined by the criteria of the UKPDSBB
* stage 1 , 2 or 3 Hoehn and Yahr (ON)
* age of onset of the disease known
* brain MRI performed during follow-up
* Huntington disease :

* genetically defined (CAG \> 35)
* weaning neuroleptic ( Tercian® and Solian® : 2 days; Haldol® : 5 days ; Tiapridal® and Xenazine : 1 day ; Zyprexa® : 4 days)
* Early stage : Fahn and Shoulson I and II is a CFT score between 7 and 13

Exclusion Criteria

* Illiteracy, writing or reading difficulties
* Visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions
* Visual hallucinations
* Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not)
* Current or previous neurological diseases other than MH or MP: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment.
* Psychiatric disorders depression unless treated (stable treatment for 1 month)
* Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month)
* Inability to achieve an autonomous operation without technical assistance over a distance of 20 meters.
* Inability to stand without technical assistance for 30 seconds.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire, Amiens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre KRYSTKOWIAK, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

CHU Amiens

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Amiens

Amiens, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI10-DR-DURU

Identifier Type: -

Identifier Source: org_study_id